| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 4978 | 2017 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1960 | 2019 |
| Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma FL Locke, SS Neelapu, NL Bartlett, T Siddiqi, JC Chavez, CM Hosing, ... Molecular Therapy 25 (1), 285-295, 2017 | 679 | 2017 |
| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, YI Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119-3128, 2020 | 618 | 2020 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 526 | 2014 |
| Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial CA Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ... The lancet oncology 23 (1), 91-103, 2022 | 395 | 2022 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 330 | 2022 |
| Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T) RM Alvi, MJ Frigault, MG Fradley, MD Jain, SS Mahmood, M Awadalla, ... Journal of the American College of Cardiology 74 (25), 3099-3108, 2019 | 277 | 2019 |
| CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products JC Chavez, C Bachmeier, MA Kharfan-Dabaja Therapeutic advances in hematology 10, 2040620719841581, 2019 | 225 | 2019 |
| Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial SS Neelapu, M Dickinson, J Munoz, ML Ulrickson, C Thieblemont, ... Nature medicine 28 (4), 735-742, 2022 | 195 | 2022 |
| Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma JM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, ... Haematologica 106 (4), 978, 2021 | 190 | 2021 |
| High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma EA Dean, RS Mhaskar, H Lu, MS Mousa, GS Krivenko, A Lazaryan, ... Blood Advances 4 (14), 3268-3276, 2020 | 171 | 2020 |
| Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort … MA Kharfan-Dabaja, A Kumar, E Ayala, M Hamadani, P Reimer, ... Biology of Blood and Marrow Transplantation 23 (11), 1826-1838, 2017 | 171 | 2017 |
| Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma MD Jain, H Zhao, X Wang, R Atkins, M Menges, K Reid, K Spitler, ... Blood, The Journal of the American Society of Hematology 137 (19), 2621-2633, 2021 | 170 | 2021 |
| NCCN guidelines insights: B-cell lymphomas, version 3.2019: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JS Abramson, RH Advani, NL Bartlett, PF Caimi, ... Journal of the National Comprehensive Cancer Network 17 (6), 650-661, 2019 | 167 | 2019 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260-2267, 2017 | 167 | 2017 |
| Cytokine release syndrome: current perspectives H Murthy, M Iqbal, JC Chavez, MA Kharfan-Dabaja ImmunoTargets and therapy, 43-52, 2019 | 156 | 2019 |
| Odronextamab, a human CD20× CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma … R Bannerji, JE Arnason, RH Advani, JR Brown, JN Allan, SM Ansell, ... The Lancet Haematology 9 (5), e327-e339, 2022 | 151 | 2022 |
| Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) C Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ... Blood 136, 40-41, 2020 | 142 | 2020 |
| Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment LM Juárez-Salcedo, L Sokol, JC Chavez, S Dalia Cancer Control 25 (1), 1073274818778256, 2018 | 141 | 2018 |
